A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer

Must have received: gemcitabine-nab-paclitaxel (gemcitabine, nab-paclitaxel) — standard of care

Patients who are candidates for and have access to gemcitabine-nab-paclitaxel ... must have received these standard of care regimens before randomization.

Must have received: FOLFIRINOX or mFOLFIRINOX (FOLFIRINOX, mFOLFIRINOX) — standard of care

or are candidates for FOLFIRINOX/mFOLFIRINOX must have received these standard of care regimens before randomization.

Cannot have received: anti-cancer chemotherapy, radiotherapy, biologic therapy or immunotherapy

Exception: allowed if completed >2 weeks prior to first planned dose of study medication

Anti-cancer chemotherapy, radiotherapy, biologic therapy or immunotherapy administered two weeks prior to the first planned dose of study medication.

Cannot have received: investigational agent

Exception: allowed if completed >4 weeks prior to first planned dose of study medication

Investigational agents administered within four weeks of first planned dose of study medication.

Cannot have received: taxane

Exception: patients intolerant to prior taxane treatment are excluded

Patient who were intolerant to prior taxane treatment.

Cannot have received: napabucasin (napabucasin)

Prior treatment with napabucasin or participation in a clinical trial evaluating napabucasin.